Clinical Trials Browser

Interventional × Central Nervous System Neoplasms × cabozantinib × Clear all

NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT05425004 2026-05-14

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Phase 2 Recruiting

24 enrolled

CNS

Meningioma, Central Nervous System Neoplasms

NCT01709435 2023-12-22

Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Phase 1 Completed

41 enrolled 20 charts

CNSDermatologicHead & Neck

Melanoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary